Claritas Pharmaceuticals Inc V.CLAS.H

Alternate Symbol(s): CLAZF

Healthcare

Claritas Pharmaceuticals, Inc., formerly Kalytera Therapeutics Inc, is a biotechnology company that is focused on developing R-107 for the treatment of vaccine-resistant coronavirus disease (COVID) strains. The Company’s products in development include R-107 for coronavirus disease and Viral Infections, R-107 and Vaccines, and CLA-1816 for treatment of pain. R-107 is designed to defeat COVID viruses on contact. R-107 targets the Achilles heel of COVID, the spike protein on the surface of the virus. R-107 releases nitric oxide, which attaches to a specific amino acid on the spike protein, thereby disabling the spike protein. The CLA-1816 provides effective pain reduction, without the risks of addiction or respiratory suppression that exist with opioid analgesics. CLA-1816 strongly binds with and activates the alpha3 glycine pain receptor in the spine. The Company has leased a laboratory, office, and archival space in Beverly, Massachusetts.

TSXV:CLAS.H - Post by User

Claritas Pharmaceuticals Inc > Company to update past 8-months work- a lot in the pipeline

<< Previous

Bullboard Posts

Next >>

Post by Rezjenon Mar 01, 2021 7:07pm

278 Views

Post# 32691476

Company to update past 8-months work- a lot in the pipeline

Read between the lines in Today's NR- as this story unfolds to the market, the world will have a solution for Covid-19

More interesting when Ceo says "We intend to become a leader in the race to find a treatment for COVID-19, and we are well positioned to achieve this goal,”

it sounds they are way ahead in the game and knows exactly what they are doing!

long enjoy the ride!!!

<< Previous

Bullboard Posts

Next >>

Who, why, and what of the great "Crypto Surge"